Related Experiment Video
Updated: May 4, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Tuberculosis elimination: theory and practice in Europe
Lia D'Ambrosio1, Masoud Dara, Marina Tadolini
1Fondazione Salvatore Maugeri, Care and Research Institute, Tradate.
European countries lack essential elements for tuberculosis (TB) elimination preparedness, despite a 1990 pathway identification. Key gaps include national TB programmes, clear targets, drug availability, and comprehensive monitoring, hindering progress towards TB elimination goals.
Area of Science:
- Public Health
- Epidemiology
- Infectious Disease Control
Background:
- Europe identified a tuberculosis (TB) elimination pathway in 1990.
- Information on country preparedness programs for TB elimination in Europe is scarce.
- Low TB incidence countries (<20 cases/100,000 population) were surveyed.
Purpose of the Study:
- To assess the preparedness of European countries for tuberculosis (TB) elimination.
- To identify existing TB elimination activities and essential preparedness elements in low TB incidence European countries.
Main Methods:
- A questionnaire was distributed to national TB programme representatives in 38 European countries/territories.
- 31 countries provided complete answers regarding their TB elimination activities.
- Data collected included national TB programs, plans, guidelines, budgets, reference centers, surveillance, supervision, M&E, and drug availability.
Main Results:
- Only 54.8% of responding countries had a dedicated national TB programme, and 41.9% had elimination plans with targets.
- 71% had guidelines, but only 45.2% had a specific TB budget.
- Drug availability was a concern, with 71% reporting unavailability of all TB drugs and 38.7% experiencing stock-outs.
- While high-risk group screening occurred, only 19.4% reported preventive treatment completion rates.
Conclusions:
- Significant gaps exist in essential elements for tuberculosis (TB) elimination preparedness across low TB incidence European countries.
- Inconsistent availability of TB drugs and challenges in preventive treatment monitoring hinder progress.
- Strengthening national TB programmes, ensuring drug supply, and improving monitoring are crucial for achieving TB elimination in Europe.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

